M. Harada

1.3k total citations · 1 hit paper
20 papers, 977 citations indexed

About

M. Harada is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, M. Harada has authored 20 papers receiving a total of 977 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in M. Harada's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (8 papers) and Colorectal Cancer Treatments and Studies (5 papers). M. Harada is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (8 papers) and Colorectal Cancer Treatments and Studies (5 papers). M. Harada collaborates with scholars based in Japan, United States and United Kingdom. M. Harada's co-authors include Hiroshi Isobe, Yasuko Fujita, Ichiro Kinoshita, Makoto Maemondo, Akira Inoue, Toshiyuki Harada, Satoshi Morita, T. Nukiwa, Koichi Hagiwara and Akihiko Gemma and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

M. Harada

20 papers receiving 956 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)

2012 427 citations Akira Inoue, Kunihiko Kobayashi et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Harada Japan	11	858	714	239	178	62	20	977
Junko Hamamoto Japan	16	535 0.6×	446 0.6×	408 1.7×	153 0.9×	61 1.0×	27	808
Luigi Guetti Italy	7	501 0.6×	346 0.5×	271 1.1×	184 1.0×	88 1.4×	14	600
Ruqin Chen United States	11	559 0.7×	511 0.7×	161 0.7×	88 0.5×	38 0.6×	22	764
Albert Reising United States	8	359 0.4×	239 0.3×	250 1.0×	193 1.1×	18 0.3×	18	591
R. Pérez-Carrión Spain	10	170 0.2×	290 0.4×	121 0.5×	163 0.9×	43 0.7×	29	489
Sakiko Otani Japan	13	404 0.5×	465 0.7×	142 0.6×	92 0.5×	30 0.5×	45	613
You‐cai Zhu China	15	307 0.4×	250 0.4×	222 0.9×	138 0.8×	47 0.8×	59	533
Hironobu Iijima Japan	12	325 0.4×	311 0.4×	253 1.1×	86 0.5×	22 0.4×	19	572
R. Rosell Spain	8	407 0.5×	376 0.5×	143 0.6×	83 0.5×	60 1.0×	21	612
Lieming Ding China	13	369 0.4×	325 0.5×	194 0.8×	42 0.2×	41 0.7×	53	616

Countries citing papers authored by M. Harada

Since Specialization

Citations

This map shows the geographic impact of M. Harada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Harada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Harada more than expected).

Fields of papers citing papers by M. Harada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Harada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Harada. The network helps show where M. Harada may publish in the future.

Co-authorship network of co-authors of M. Harada

This figure shows the co-authorship network connecting the top 25 collaborators of M. Harada. A scholar is included among the top collaborators of M. Harada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Harada. M. Harada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yamamoto, Ryoko, et al.. (2024). Luteolin enhances oxidative stress tolerance via the daf-16 pathway in the nematode Caenorhabditis elegans. Food Science and Technology Research. 30(2). 253–260. 2 indexed citations

Felip, Enriqueta, Martin Reck, Rüediger Liersch, et al.. (2022). 1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC). Immuno-Oncology Technology. 16. 100106–100106. 13 indexed citations

Zhou, C., Meghna Das Thakur, Manoj Srivastava, et al.. (2021). 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC. Annals of Oncology. 32. S1374–S1374. 41 indexed citations

Nishio, Makoto, Katsuyuki Kiura, Takashi Seto, et al.. (2017). OA 05.08 Final Result of Phase I/II Study (AF-001JP) of Alectinib, a Selective CNS-Active ALK Inhibitor, in ALK+ NSCLC Patients (Pts). Journal of Thoracic Oncology. 12(11). S1757–S1757. 1 indexed citations

Takeuchi, Kengo, Yosuke Togashi, T. Fukuyama, et al.. (2015). Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study). Annals of Oncology. 27(1). 185–192. 39 indexed citations

Sugawara, Shunichi, Satoshi Oizumi, Koichi Minato, et al.. (2015). Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. Annals of Oncology. 26(5). 888–894. 92 indexed citations

Tsukada, Hiroko, Akira Yokoyama, Kōichi Goto, et al.. (2014). Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207. Japanese Journal of Clinical Oncology. 45(1). 88–95. 22 indexed citations

Katakami, Nobuyuki, Hiroshige Yoshioka, Hiroaki Okamoto, et al.. (2014). Amrubicin (Amr) Versus Docetaxel (Dtx) As Second- or Third-Line Treatment for Non-Small Cell Lung Cancer (Nsclc): a Randomized Phase III Trial. Annals of Oncology. 25. iv432–iv432. 3 indexed citations

Tamura, Tomohide, Takashi Seto, Kazuhiko Nakagawa, et al.. (2014). Updated Data of a Phase 1/2 Study (AF-001JP) of Alectinib, a CNS-Penetrant, Highly Selective ALK Inhibitor in ALK-rearranged Advanced NSCLC. International Journal of Radiation Oncology*Biology*Physics. 90(5). S6–S6. 13 indexed citations

10.

Inoue, Akira, Kunihiko Kobayashi, Makoto Maemondo, et al.. (2012). Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Annals of Oncology. 24(1). 54–59. 427 indexed citations breakdown →

11.

Nishio, Makoto, Katsuyuki Kiura, Kazuhiko Nakagawa, et al.. (2012). A Phase I/II Study of Alk Inhibitor CH5424802 in Patients With Alk-Positive Nsclc; Safety and Efficacy Interim Results of the Phase II Portion. Annals of Oncology. 23. ix153–ix153. 12 indexed citations

12.

Fujita, Yasuko, Hiroshi Yokouchi, S Fujiuchi, et al.. (2012). Phase II Trial of Carboplatin and Pemetrexed as First-Line Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer and Correlation Between the Efficacy/Toxicity and Genetic Polymorphisms Associated with Pemetrexed Metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902. Annals of Oncology. 23. ix434–ix434. 1 indexed citations

13.

Hata, Akito, Hiroshi Kunikane, Koji Takeda, et al.. (2011). Prospective study on incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer (CSP-HOR13).. Journal of Clinical Oncology. 29(15_suppl). 7545–7545. 9 indexed citations

14.

Ishida, Takashi, Kenya Kanazawa, Hiroaki Oizumi, et al.. (2007). Phase II study of meloxicam with carboplatin plus docetaxel in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 18121–18121. 1 indexed citations

15.

Asahina, Hajime, K Yamazaki, Ichiro Kinoshita, et al.. (2006). A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. British Journal of Cancer. 95(8). 998–1004. 235 indexed citations

16.

Fujimoto, Nobukazu, et al.. (2002). Lung cancer prevention with (-)-epigallocatechin gallate using monitoring by heterogeneous nuclear ribonucleoprotein B1. International Journal of Oncology. 20(6). 1233–9. 35 indexed citations

17.

Ueoka, Hiroshi, Masahiro Tabata, Katsuyuki Kiura, et al.. (1999). Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study. British Journal of Cancer. 79(5-6). 984–990. 18 indexed citations

18.

Maki, Hideo, et al.. (1999). [A giant invasive thymoma made resectable by cisplatin + vincristine + doxorubicin + etoposide (CODE)].. PubMed. 26(5). 697–701. 2 indexed citations

19.

Yoshida, Masami, et al.. (1994). Lymphocutaneous nocardiosis with multiple subcutaneous nodules distributed over the extensor aspect of the forearm. Report of a case.. Acta Dermato Venereologica. 74(6). 447–448. 6 indexed citations

20.

Okamoto, Tatsuya, et al.. (1970). [Experimental pulmonary fibrosis induced by bleomycin].. PubMed. 80(6). 299–301. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact